© 2005-2012 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.
Research Summaries
Using the drop-down menu below, read about highlighted scientific news from ASCO's Annual Meetings since 2002. You can select a specific year and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
The 2013 ASCO Annual Meeting is set for May 31-June 4, with research news beginning to be released on May 15 at 6pm Eastern. Additional research will be released each day of the meeting.
To read these summaries categorized into a yearly newsletter, you can also review Cancer Advances: News for Patients from the ASCO Annual Meeting.
Don’t forget to check out audio podcasts and videos about this news, as well. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at the ASCO Annual Meeting. To search the entire collection of meeting abstracts, visit ASCO's website.
May 31, 2009
Researchers found that a vaccine called BiovaxID delayed the return of a type of B-cell lymphoma, called follicular lymphoma, by about 14 months for patients whose lymphoma was in remission (the temporary or permanent absence of disease) after treatment with prednisone (multiple brand names), doxorubicin (Adriamycin), cyclophosphamide (Cytoxan, Clafen, Neosar), and etoposide (VePesid, Toposar) - a combination called PACE. The BiovaxID vaccine is made for each patient using proteins that are found on the person's lymphoma cells. It is made from the cells collected during removal of the lymph nodes (tiny, bean-shaped organs that help fight infection). These cells are then processed to create antibodies, which are substances made by the body to help fight infection. These antibodies are designed to kill the patient's own lymphoma cells and are returned to the patient in the form of a vaccine.
May 31, 2009
Researchers found that patients with non-small cell lung cancer (NSCLC) whose tumors had no or low levels of a protein called MSH2, benefitted more from chemotherapy after surgery than patients with high levels of MSH2. Cancer cells use the MSH2 protein to repair damage from chemotherapy with cisplatin (Platinol). Patients with low MSH2 levels who received chemotherapy with cisplatin lived about 16 months longer than those who did not receive chemotherapy. Patients with high MSH2 levels who received chemotherapy lived for about 9 months less than those who did not receive chemotherapy. This study also showed that measuring MSH2 levels and levels of another protein called ERCC1 was better able to predict which patients would benefit from chemotherapy after surgery. ERCC1 is a previously identified protein that also repairs damage to tumor cells. Patients with low levels of both proteins who received chemotherapy lived 26 months longer than those who did not receive chemotherapy.
May 31, 2009
A new study showed that patients who received moisturizers, sunscreen, topical steroids, and antibiotics before treatment with panitumumab (Vectibix) were less likely to have a rash from treatment than patients who did not receive the skin treatments until the rash developed. About 90% of people taking panitumumab and 75% of those taking a related drug called cetuximab (Erbitux) develop this rash.
May 31, 2009
In two separate studies, researchers found that two new drugs belonging to a group of drugs called PARP inhibitors may help treat some types of breast cancer. PARP inhibitors stop cancer cells from repairing damage from chemotherapy, which may make cancer cells more sensitive to chemotherapy.
May 31, 2009
New studies on breast cancer recurrence look at radiation therapy techniques, drugs that may interfere with tamoxifen (Nolvadex), and the removal of lymph nodes (tiny, bean-shaped organs that help fight infection).
May 30, 2009
New research shows advances in the treatment of colorectal, anal, pancreatic, gastric, and rectal cancer.
May 30, 2009
Two studies showed that treatment with targeted therapy drugs (drugs that target the faulty genes and proteins that contribute to cancer growth) slowed the growth and spread of advanced NSCLC.
May 30, 2009
A new study shows that patients who received a specialized treatment vaccine with interleukin-2 (IL-2; a standard treatment for advanced melanoma) for melanoma that has spread to other parts of the body lived almost five months longer than patients who received only IL-2. The vaccine used in this study is made from part of a protein (substance in the body that helps it to function) found on melanoma cells that helps the cancer grow. This study also showed that treatment caused the melanoma to stop growing or shrink for more than twice as many patients who received the vaccine and IL-2 than those who received only IL-2.
May 30, 2009
Researchers found that most patients with metastatic colorectal cancer (cancer that has spread outside of the colon or rectum) do not need surgery to remove the primary tumor unless it is causing problems. Removing the primary tumor when a person is diagnosed with metastatic colorectal cancer was once the standard treatment and is still common. Surgery has been used to prevent the tumor from blocking the intestines, creating a hole in the wall of the intestine, or causing bleeding. Chemotherapy is an effective treatment for metastatic colorectal cancer because it can often shrink both the primary tumor and the cancer that has spread to other areas.
May 30, 2009
Patients with advanced non-small cell lung cancer (NSCLC) who received the drug pemetrexed (Alimta) as maintenance therapy (treatment given after chemotherapy to keep the cancer from growing and spreading) lived three to five months longer than patients who did not receive the drug, according to a new study. This study also confirmed that the benefit of maintenance therapy is greater for patients with the nonsquamous type of NSCLC.